دورية أكاديمية
أعرض في EDS

Evaluation of factors predicting the benefit from systemic oncological treatment for severely ill hospitalized patients: a retrospective study.

التفاصيل البيبلوغرافية
العنوان: Evaluation of factors predicting the benefit from systemic oncological treatment for severely ill hospitalized patients: a retrospective study.
المؤلفون: Neves MBM; Centro Universitário Faculdade de Medicina do ABC (FMABC), Santo André, SP, Brazil. milenabrachmans@gmail.com.; Hospital Alemão Oswaldo Cruz, 212. Vila Mariana, 0412601, São Paulo, SP, Brazil. milenabrachmans@gmail.com., Neves YCS; Instituto de Radiologia (InRad), Faculdade de Medicina, Hospital das Clinicas HCFMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil., Bomonetto JVB; Centro Universitário Faculdade de Medicina do ABC (FMABC), Santo André, SP, Brazil., Matos PPC; Centro Universitário Faculdade de Medicina do ABC (FMABC), Santo André, SP, Brazil., Giglio AD; Centro Universitário Faculdade de Medicina do ABC (FMABC), Santo André, SP, Brazil., Cubero DIG; Centro Universitário Faculdade de Medicina do ABC (FMABC), Santo André, SP, Brazil.
المصدر: BMC palliative care [BMC Palliat Care] 2023 Sep 06; Vol. 22 (1), pp. 131. Date of Electronic Publication: 2023 Sep 06.
نوع المنشور: Observational Study; Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101088685 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-684X (Electronic) Linking ISSN: 1472684X NLM ISO Abbreviation: BMC Palliat Care Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2002-
مواضيع طبية MeSH: Medical Oncology* , Inpatients*, Humans ; Retrospective Studies ; Brazil ; Albumins
مستخلص: Background: Patients with cancer in the disease's end-stage with poor performance represent a challenging clinical scenario, as they have high chance of a fatal outcome due to clinical conditions, oncological emergencies, and/or metastatic disease. This study examines the factors predicting the potential benefit of "urgent" chemotherapy during hospitalization in this setting, thus addressing a research gap.
Methods: This retrospective observational study was conducted in the largest cancer center in the outskirts of São Paulo. It identified factors predicting the benefit from antineoplastic treatment in severe in-hospital patients admitted during 2019-2020, considering post-chemotherapy survival time as the main dependent variable. Data were retrieved from medical records. All patients aged ≥ 18 years, with an ECOG-PS score ≥ 2, and undergoing non-elective systemic cancer treatment were included.
Results: This study evaluated 204 records, of which 89 were included in the final analysis. A statistically significant association with the worse outcome (death within 30 days of chemotherapy) was found with higher ECOG performance status; chemotherapy dose reduction; lower values of serum albumin, hemoglobin, and creatinine clearance; and higher values of leukocytes, neutrophils, direct bilirubin, urea, and C-reactive protein. In the multivariate analysis, only albumin remained statistically associated with the outcome (hazard ratio = 0.35; confidence interval: 0.14, 0.90; p = 0.034).
Conclusions: Serum albumin and other clinical and laboratory variables might be associated with early post-treatment deaths in patients with cancer. The study data might help guide the decision to administer systemic treatment in this scenario and manage critically ill patients. This study adds to our knowledge of the factors predicting the objective benefits from "heroic" or "urgent" chemotherapy for hospitalized and severely ill patients with cancer.
(© 2023. BioMed Central Ltd., part of Springer Nature.)
References: World J Oncol. 2018 Feb;9(1):13-20. (PMID: 29581811)
Gynecol Oncol. 2022 Jan;164(1):146-153. (PMID: 34802721)
Neurology. 2014 Aug 5;83(6):486-93. (PMID: 24991031)
Cancer. 2014 Jun 1;120(11):1743-9. (PMID: 24967463)
Support Care Cancer. 2015 Nov;23(11):3277-80. (PMID: 25900109)
Target Oncol. 2018 Apr;13(2):247-252. (PMID: 29404898)
Dtsch Arztebl Int. 2021 Apr 23;118(17):. (PMID: 33531117)
Anticancer Res. 2021 Jun;41(6):3131-3137. (PMID: 34083307)
Curr Oncol. 2014 Aug;21(4):187-92. (PMID: 25089101)
JAMA. 2008 Jun 11;299(22):2667-78. (PMID: 18544726)
Am J Hosp Palliat Care. 2020 Aug;37(8):641-647. (PMID: 31968989)
BMC Palliat Care. 2019 May 20;18(1):42. (PMID: 31109330)
Int J Mol Sci. 2021 Jul 27;22(15):. (PMID: 34360768)
BMC Palliat Care. 2015 Nov 16;14:61. (PMID: 26572617)
J Clin Oncol. 2006 Jul 20;24(21):3490-6. (PMID: 16849766)
Tumori. 2010 May-Jun;96(3):443-7. (PMID: 20845806)
Intensive Care Med. 2017 Sep;43(9):1366-1382. (PMID: 28725926)
Clin Transl Oncol. 2011 Jun;13(6):426-9. (PMID: 21680304)
J Intensive Care Med. 2020 Apr;35(4):347-353. (PMID: 29258386)
J Pain Symptom Manage. 1999 Apr;17(4):231-9. (PMID: 10203875)
Cochrane Database Syst Rev. 2017 Jun 12;6:CD011129. (PMID: 28603881)
BMC Palliat Care. 2011 Sep 21;10:14. (PMID: 21936940)
Int J Surg. 2018 Jul;55:128-138. (PMID: 29807167)
CA Cancer J Clin. 2017 Mar;67(2):93-99. (PMID: 28094848)
J Palliat Med. 2010 Jul;13(7):831-5. (PMID: 20636153)
J Clin Oncol. 2011 Sep 1;29(25):3457-65. (PMID: 21810685)
فهرسة مساهمة: Keywords: Chemotherapy; ECOG; End of life; Hospital medicine; Palliative care; Patients with cancer; Systemic oncological treatment
المشرفين على المادة: 0 (Albumins)
تواريخ الأحداث: Date Created: 20230906 Date Completed: 20230908 Latest Revision: 20231122
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10481478
DOI: 10.1186/s12904-023-01256-8
PMID: 37674155
قاعدة البيانات: MEDLINE
الوصف
تدمد:1472-684X
DOI:10.1186/s12904-023-01256-8